Radiation-induced mucositis is an acute reaction of the mucosa of patients undergoing head and neck radiotherapy. It can have debilitating and dose-limiting consequences. There is no consensus on an accepted intervention that significantly reduces its severity. Misoprostol is a synthetic prostaglandin E1 analogue, with properties of a mucosal cytoprotectant. We designed a randomized, double-blind, placebo-controlled trial of misoprostol in patients with head and neck cancer. The aim of this study was to determine if topical misoprostol was effective in reducing the severity of radiation-induced mucositis in patients receiving radical dose radiotherapy. The effect of this intervention on a patient's general well-being was also investigated. The primary end-point of the study was the incidence of Radiation Therapy Oncology Group grade 3 mucositis. Between 1999 and 2002, 83 patients were recruited into the study at Westmead and Nepean Hospitals, Sydney. Forty-two patients were randomized to receive misoprostol and 41 to receive a placebo. Most patients received radiotherapy in the adjuvant setting (52 of the 83) and had either an oral cavity (42 of the 83) or an oropharyngeal (16 of the 83) cancer. We could not identify any significant difference in the incidence of severe mucositis based on whether patients were allocated to receive misoprostol or placebo. There was no significant difference in the mean area under the mucositis curve (13.2 vs 16.6; P = 0.1). Patients allocated to misoprostol did report slightly increased soreness (7.6 vs 6.9; P = 0.04) and a greater use of analgesics. However, this difference did not translate into a worse feeling of general well-being as measured by a simple visual analogue scale (5.8 vs 5.2; P = 0.3). In conclusion, we were unable to identify a reduction in radiation-induced mucositis in patients receiving misoprostol. There is a paucity of high-level evidence on potentially useful interventions and a continued need for new and innovative research, incorporating quality-of-life measurements, in patients experiencing radiation-induced mucositis.
Younger patients (< or = 50 years of age) develop lung cancer. Many series report 5-10% of all cases occurring in younger patients. Outcome, inspite of treatment, is universally poor. Females and adenocarcinomas are over-represented and the aetiology for such an early-age presentation is unclear. The aims of this retrospective study were to review the clinical characteristics, treatment details and outcome of patients aged 50 years or younger diagnosed with lung cancer (small cell and non-small cell). Over a period of 34 months, 497 lung cancer patients were treated at the Liverpool Hospital Cancer Therapy Centre. Thirty-seven (7.4%) patients aged less than or equal to 50 years were identified. The median age at diagnosis was 44 years (range 32-49 years) in 20 females and 17 males. Adenocarcinoma was the predominant histological subtype (32%). No referred patient had stage I/II disease. Almost 90% of patients were smokers. Median survival following diagnosis was 12 months (range, 9 days-68 months) with 70% having died by the close of study. The clinical characteristics and outcome of young patients in our study were comparable to other similar series.
The breast is a complex anatomical structure where achieving a homogeneous dose distribution with radiation treatment is difficult. Despite obvious similarities in the approach to such treatment (using tangents) there is variation in the process of simulation, planning and treatment between radiation oncologists. Previous Australasian studies in the treatment of lung cancer, prostate cancer and Hodgkin's disease highlighted considerable variation in many areas of treatment. As part of a multicentre breast phantom study involving 10 radiation oncology departments throughout New South Wales (NSW) and the Australian Capital Territory (ACT), a 22-question survey was distributed. The aim of the survey was to assess the extent of variation in the approach to the simulation, planning and treatment of early breast cancer using tangents. Responses from 10 different radiation oncology departments revealed variation in most areas of the survey. There is no reason to assume similar variations do not occur Australasia wide. Studies involving overseas radiation oncologists also reveal a wide variation in treating early breast cancer. The consequences of such variations remain unclear.
Dis€ase Recurrsnce Predictors for Patients wilh Head and Neck Squamous Cell Carcinoma lnformationonreliablefactorslopredictpatientoutcomeisimportantfordecidinguponthebes treatment to increase loco-regional control, overall survival and quali'y oflife ofpalients with head and neck s,ruanous cell carcinoma ([NSCC). The objective of this studv was to invesligate the role of clinico-"]ir,oroni"uf o*ut.r." ns predictors ofdisease recurrence in patients with HNScc we studied fifty patients i"r," '.-t. .J"f'"g trcatment for primary HNSCC in Westmead Hospital between 2002-2004' tjnivariate anatysis was used-ro identi! any signrficant associalion between clinico-pathological param€lers and disease .".,it"r"". r, *u. .rto*.d that ieeip=0 0ost, cTNM stage (p=0 02), size of tumour (p=0 009) and positive iumour margin (p:0.002) prerticted the risk ofthe development ofdisease recunen€e ln agrcernen with other ,tua;", *" fiuni t6ur .or" tradilional factors influenced diseas€ recu.€nce. A longer follow'up study should beperformedloassessth€significanceofth€sefactorsonoverallsurvivalaswellasseparatestudl prolnl"ti" indi"otors fo. paie;ts wilh histologically negative lvmph node lndonesian loutnal of Dentisttv 2a06 Edisi Khusus KPPIKC XlV.362-367
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.